Interferons (IFNs) are cytokines that are involved in the regulation of diverse cellular functions, including modulation of immune responses, inhibition of proliferation, and induction of resistance to viral and bacterial infection (Gutterman, 1994) . IFNs employ a unique signalling pathway for rapid induction of gene expression by utilizing two groups of critical elements to transduce the signals from cell surface receptor to nuclear events. The first is the janus family kinases (JAKs), a group of tyrosine kinases containing JAK1, JAK2, JAK3 and TYK2, and the second is STAT (signal transducers and activators of transcription) proteins, a group of latent cytoplasmic transcription factors which are activated by phosphorylation (Darnell, 1997; Pellegrini and Dusanter-Fourt, 1997) . Upon IFN stimulation, receptor-associated JAKs are phosphorylated and activated and these kinases, in turn, phosphorylate and activate STAT proteins which then translocate from cytoplasm to nucleus and direct transcriptional activation of various effector genes. The essential role of JAKs and STATs in IFN signalling pathway has been demonstrated by the IFN-resistant phenotypes of cells lacking the JAK or STAT gene products (Muller et al, 1993; Xu et al, 1994) .
B. These cytokines have been reported to suppress hepatitis B virus (HBV) enhancer activity, reduce virus replication and activate hepatocellular gene expression in cultured liver cells (Tur-Kaspa et al, 1990; Zhang and McLachlan, 1994) . Additionally, results from clinical trials also demonstrated that IFNs caused inhibition of HBV replication and reduction of hepatitis B surface antigen (HBsAg) expression (Alexander et al, 1987; Korenman et al, 1991) . These studies suggest that IFNs are useful anti-viral drugs for the treatment of patients with viral hepatitis. However, the use of IFNs in the therapy of liver cancer seems discouraging. Although several studies have shown that IFNs exerted growth-inhibitory effects on human hepatoma cells (Lai et al, 1989; Boue et al, 1990 ), other works showed that patients with advanced hepatocellular carcinoma were resistant to IFNs (Nair et al, 1985; Sachs et al, 1985) . However, the molecular basis of this resistance is not clear.
Recent studies have indicated that the responses of cells to IFNs could be modulated by regulating the expression or the activity of JAKs and STATs. It has been found that elevated activity of JAKs enhanced the anti-tumour effects of IFNs to lymphoblastoid cells (Lee et al, 1997) . Similarly, induction of STATs gene expression by retinoic acids in IFN-unresponsive breast cancer cells and myeloid leukaemia cells permitted growth inhibition by IFNs (Kolla et al, 1996; Weihua et al, 1997) . These data suggest that the resistance of cancer cells to IFNs may be due to a relative deficiency of IFN signalling molecules and argue that overexpression of these signalling molecules may restore the responsiveness of cancer cells to IFNs. Among the drugs examined, differentiation-inducing agents were found to be effective both in enhancing STATs expression and in promoting IFN-α-induced cell growth arrest in different tumour types (Goto et al, 1996; Pelicano et al, 1997) . We have previously demonstrated that sodium butyrate, a natural fermentation product of colonic bacterial flora, induced differentiation in PLC/PRF/5 hepatoma cells (Hung et al, 1995) . In this study, we investigated whether sodium butyrate modulated the expression of STATs in PLC/PRF/5 cells and altered the sensitivity of these cells to IFN-α.
MATERIALS AND METHODS

Reagents
Human recombinant IFN-α was kindly provided by Hoffmann-La Roche Inc. Antibodies against the members of the STAT gene family (STAT1-6) were obtained from Transduction Laboratories (Lexington, KY, USA) and monoclonal antibodies against human cyclin D1 and p21 WAF-1 were purchased from Calbiochem (San Diego, CA, USA). Anti-human retinoblastoma protein (pRB) antibody was obtained from Pharmingen (San Diego, CA, USA) and sodium butyrate and other chemicals were purchased from Sigma (St Louis, MO, USA).
Cell culture and treatment
PLC/PRF/5 cells were cultured in Dulbecco's modified Eagle medium: nutrient mixture F12 (DMEM/F12) supplemented with 10% heat-inactivated fetal calf serum (FCS) in a 5% carbon dioxide incubator at 37ЊC. Cells were grown in 10% FCS medium to subconfluence and then incubated in medium containing sodium butyrate (1 mM) or IFN-α (200-2000 IU ml Ϫ1 ) alone, or a combination of these two drugs for different time intervals, and were harvested for analysis.
Analysis of cell cycle phase by flow cytometry
The drug-treated cells were trypsinized, washed with phosphatebuffered saline (PBS) and fixed in 95% ethanol at Ϫ 20ЊC for 1 h. Following collection, cells were resuspended in 400 µl of PBS containing 1 mg ml Ϫ1 RNAase and 0.5% Triton X-100, incubated at room temperature for 1 h and stained with 50 µg ml Ϫ1 of propidium iodide for another 30 min. Fluorescence emitted from the propidium iodide-DNA complex was analysed by FACScan flow cytometry (Becton Dickinson) and cell cycle distribution was calculated with the CellFit software.
Immunoprecipitation and immunoblotting
After treatment, cells were washed with ice-cold PBS and harvested in a lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM, sodium chloride, 5 mM EDTA, 1% Triton X-100, 50 mM sodium fluoride (NaF), 1 mM sodium orthovanadate, 1 mM phenylmethylsulphonyl fluoride, 2 µg ml Ϫ1 pepstatin A, 2 µg ml Ϫ1 leupeptin and 1 µg ml Ϫ1 aprotinin) for 20 min on ice and centrifuged at 12 000 g for 20 min. Protein concentration of lysates was determined by using a Bio-Rad protein assay kit. For immunoprecipitation, normalized volumes of extracts containing 500 µg protein were incubated for 4 h at 4ЊC with specific antibodies. Immunocomplexes were collected following incubation with protein Gagarose beads at 4ЊC for another 1 h. The beads were washed three times with lysis buffer and the immunocomplexes were eluted by boiling in the Laemmli sample buffer. Equal volumes of eluted immunocomplexes were then subjected to immunoblotting analysis. For immunoblotting, eluted immunocomplexes or cell lysates (50 µg protein per sample) were subjected to sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were transferred to nitrocellulose filters and the blots were blocked overnight at 4ЊC in 5% non-fat milk in TBST (20 mM Tris-HCl, pH 7.4, 137 mM sodium chloride and 0.05% . The blots were washed in TBST and incubated with various antibodies for 2 h at room temperature. After extensively washing in TBST buffer, peroxidase-conjugated secondary antibody was added in blocking buffer for another 1 h and the blots were developed by using the ECL chemiluminescence system (Amersham). The signal intensities of immunoblots were quantified by densitometric scanning.
Electrophoretic mobility shift assay
Nuclear extract preparation and electrophoretic mobility shift assay EMSA analysis was performed as previously described (Decker et al, 1991) . In brief, a double-stranded oligonucleotide corresponding to the GAS element found within the promoter of the guanylate-binding protein (GBP) gene was synthesized and end-labelled using polynucleotide kinase and [γ-32 P]-adenosine 5′-triphosphate (ATP) and incubated with nuclear extracts for 20 min at room temperature. The oligonucleotide-protein complexes were fractionated on a 6% non-denatured polyacrylamide gel and detected by autoradiography. For competition, a 20-fold excess of unlabelled oligonucleotides or 1 µg anti-STAT 1 or anti-c-Jun antibodies were added to reaction mixture.
Morphological analysis of apoptotic cells
Cells were cultured in 6-well plates in complete medium containing different combinations of drugs for 72 h. After incubation, detached cells were pelleted by centrifugation and attached cells were harvested by trypsinization. Cells were pooled and collected at 3000 g for 10 min and washed twice with PBS. Cells were fixed with 3% paraformaldehyde in PBS for 15 min at room temperature and stained with Hoechst 33258 dye for another 15 min at room temperature. Stained cells were placed on glass slides and observed under a fluorescence microscope. For each sample, 500 cells were counted and apoptotic cells with condensed chromatin fragments were scored and expressed as a percentage of total cell number measured.
DNA extraction and agarose gel electrophoresis
After drug incubation, cells were harvested and genomic DNA was extracted and analysis of DNA fragmentation on agarose gel was performed as described previously (Hung and Chuang, 1996) .
RESULTS
Specific induction of STAT1 expression by sodium butyrate in PLC/PRF/5 cells
Our previous results have indicated that sodium butyrate is a potent differentiation-inducing agent to PLC/PRF/5 hepatoma cells. This agent effectively inhibited α-fetoprotein secretion, increased albumin expression and caused PLC/PRF/5 cells to acquire in vitro properties which were more consistent with welldifferentiated cells in a dose-dependent manner (Hung et al, 1995) . Since sodium butyrate at 1 mM induced phenotypic changes in PLC/PRF/5 cells as described above and did not show any cytotoxicity in these cells after a 3-day treatment, we therefore routinely used 1 mM sodium butyrate to treat cells in this work. Similar results were observed when higher concentrations of sodium butyrate were added (data not shown). We first asked whether sodium butyrate modulated the expression of STATs in this cell line. As shown in Figure 1 , PLC/PRF/5 cells cultured in 10% FCS medium constantly expressed all STATs, except STAT4, proteins. However, significant differences between the expression levels of STATs in this cell line were found. PLC/PRF/5 cells expressed a large amount of STAT6 and a relatively smaller amount of STAT1, STAT3 and STAT5, while very little amount of STAT2 was detected. Lack of STAT4 in PLC/PRF/5 cells is not surprising because the expression of STAT4 has been reported to be limited to thymus, spleen and testis (Yamamoto et al, 1994) . The difference between the expression of STATs was further confirmed by probing the membrane with anti-β-actin antibody to verify equal loading of proteins in each lane. Figure 1 also shows that sodium butyrate did not regulate the expression of STAT 3, 5, 6 in PLC/PRF/5 cells after a 48-h incubation and this agent slightly decreased the protein level of STAT2 under the same experimental conditions. Conversely, the expression of STAT1 was significantly (a 2.25-fold increase) enhanced after treatment with sodium butyrate for 2 days. Also, the difference in protein levels of STATs detected by immunoblotting is not due to the difference of quality of the used antibodies, because positive controls (lystates of Jurkat human leukaemia cells or rat testis provided by the manufacturer of antibodies) were included in our immunoblotting assays to confirm the results. Furthermore, the relative signal intensities of STATs (normalized with the signal intensities of β-actin) after sodium butyrate treatment are shown in Table 1 .
Sodium butyrate enhances the activation of STAT1 by IFN-α
Since sodium butyrate significantly up-regulates the expression of STAT1, we investigated whether IFN-α-induced phosphorylation and activation of STAT1 was enhanced in sodium butyratepretreated PLC/PRF/5 cells. The phosphorylation status of STAT1 was studied by immunoprecipitation and immunoblotting technique. Cells were preincubated with sodium butyrate for 2 days and then stimulated with different concentrations of IFN-α for 30 min. STAT1 protein was immunoprecipitated by a specific monoclonal antibody, resolved by SDS-PAGE and transferred to nitrocellulose membranes. The blots were then probed with an anti-phosphotyrosine antibody to investigate the phosphorylation status of STAT1. As demonstrated in Figure 2 , phosphorylation of STAT1 was slightly induced by IFN-α in PLC/PRF/5 cells. After sodium butyrate pretreatment, IFN-α-induced phosphorylation of STAT1 was significantly enhanced, but sodium butyrate alone did not affect the phosphorylation status of STAT1. Because STAT1 is activated by phosphorylation, we next examined whether the DNA binding activity of STAT1 was also augmented by sodium butyrate in PLC/PRF/5 cells. It is well-known that IFN-α can regulate various gene expressions via two promoter motifs called the IFN-stimulated response element (ISRE) and the IFN-γ activation site (GAS), which bind the primary factor IFN-stimulated gene factor-3 (ISGF-3) and IFN-γ activation factor (GAF) respectively. The ISGF-3 complex contains phosphorylated STAT1, STAT2 and a p48 protein, and the GAF complex mainly contains phosphorylated STAT1:STAT1 homodimer or STAT1:STAT3 heterodimer. Because the foregoing experiments indicated that the expression of STAT2 was very low in PLC/PRF/5 cells and the expression of STAT1 was specifically activated by sodium butyrate, we therefore used a GAS oligonucleotide probe to evaluate the DNA binding activity of STAT1. Figure 3 shows that IFN-α activated GAF binding to GAS in PLC/PRF/5 cells in a dose-dependent manner. Interestingly, two gel shift complexes (GAF-1 and GAF-2) with similar characteristics were observed in our EMSA autoradiographs. Similar results have also been reported in HL60 and WISH cells after IFN-α stimulation, and these complexes have been shown to be STAT1:STAT3 (GAF-1) heterodimer and STAT1:STAT1 (GAF-2) homodimer respectively (Pelicano et al, 1997) . The identity of these gel shift complexes as GAFs containing STAT1 was established by specific anti-STAT1 antibodies that neutralized the formation of GAF complexes but not by unrelated anti-c-Jun antibodies. Furthermore, unlabelled GAS oligonucleotides competed efficiently for GAF binding. Taken together, these data indicate that IFN-α-induced phosphorylation and activation of STAT1 is enhanced by sodium butyrate in PLC/PRF/5 cells.
Sodium butyrate and IFN-α synergistically induce G1 growth arrest and apoptosis in PLC/PRF/5 cells
Because sodium butyrate-preincubated PLC/PRF/5 cells showed an increase in phosphorylation and activation of STAT1 after a short-term stimulation of IFN-α, it is of interest to determine if sodium butyrate can modulate the biological responses to IFN-α in these cells after a long-term culture. Thus, cells were treated with different combinations of drugs and cell cycle distribution was examined by flow cytometry. As shown in Table 2 , the percentage of cells accumulated in G1 phase after treatment with 1 mM sodium butyrate or 2000 IU ml Ϫ1 IFN-α for 48 h was 54% and 61%, respectively, while the percentage of G1 cells was 43% in untreated cells. However, 84% of cells were in G1 phase after incubation of PLC/PRF/5 cells with 2000 IU ml Ϫ1 IFN-α and sodium butyrate simultaneously for 48 h. These results indicate that cell cycle progression was arrested in G1 phase. We further investigated the effect of these two drugs on the expression of cell cycle regulatory proteins in PLC/PRF/5 cells. As demonstrated in Figure 4 , sodium butyrate (1 mM) or IFN-α (2000 IU ml Ϫ1 ) alone slightly decrease the expression of cyclin D1, but simultaneous incubation of these two drugs completely inhibits the expression of cyclin D1. Furthermore, these two drugs synergistically activated the expression of p21 WAF-1 , a specific cyclin-dependent kinase (CDK) inhibitor. Up-regulation of p21 WAF-1 and downregulation of cyclin D1 leads to accumulation of hypophosphorylated form of retinoblastoma (Rb) proteins in these cells (Figure 4) . Additionally, we found that cell viability was dramatically decreased after co-treatment of these two drugs for 3 days. After drug treatment for 48 or 72 h, cells were fixed and stained with the fluorochrome Hoechst 33258, and apoptotic cells with condensed chromatin fragments were observed under a fluorescence microscope and scored. The percentage of apoptoic nuclei in cells co-treated with sodium butyrate and IFN-α for 72 h is about 50%, but incubation with either drug alone did not significantly affect cell viability under the same experimental conditions (Table 3) . Additionally, a characteristic DNA ladder pattern of DNA fragmentation was induced by co-treatment of these two drugs in PLC/PRF/5 cells ( Figure 5 ). Conversely, incubation of sodium butyrate or IFN-α alone for 3 days did not induce DNA fragmentation in these cells. Thus, it is suggested that long-term treatment of sodium butyrate in combination with IFN-α may trigger apoptosis in PLC/PRF/5 hepatoma cells.
DISCUSSION
The molecular mechanism for the deficiency of effects of IFNs in the inhibition of proliferation in hepatoma cells is not well defined, it is suggested that the insufficiency of expressions of important signal transducers in the IFN-mediated pathway in human hepatoma cells may be responsive partially for this deficiency. Therefore, we tested whether enhancement of the expressions of these signal transduction molecules in human hepatoma cells may restore the response of these cells to IFNs. We found that the expression of STAT1, a transcription factor involved in the IFN-mediated signalling system, is specifically activated by sodium butyrate, and phosphorylation and activation of STAT1 induced by IFN-α is also significally enhanced by this drug. In agreement with our expectation, sodium butyrate augments the anti-proliferative effect of IFN-α. Pretreatment of IFN-unresponsive tumour cell lines with retinoic acid, another potent differentiation-inducing agent, also permitted growth inhibition by IFNs (Pelicano et al, 1997; Weihua et al, 1997) . These studies indicated that augmentation of the expression of STAT1 by retinoic acid is an early step in the cooperative anti-tumour effects of retinoic acid and IFNs. In addition to in vitro study, clinical studies also demonstrated that IFN-α and 13-cis-retinoic acid produced substantial therapeutic benefits in patients with advanced squamous cell carcinomas of the skin and cervix (Lippman et al, 1992a (Lippman et al, , 1992b . Therefore, it is suggested that a rational combination of IFNs and differentiation-inducing agents may help to develop a new strategy for the treatment of human cancer. Our results support this idea and define a molecular basis for the synergy between IFNs and sodium butyrate in hepatoma growth inhibition. Furthermore, a recent study has reported that hepatitis B viral terminal protein shuts off IFN-induced gene expression by interfering with the formation of ISGF-3 and inhibited cellular responses to IFN-α and IFN-γ (Foster et al, 1991) . The authors suggested that, in patients with chronic hepatitis B virus infection, an imbalance in HBV RNA and polymerase production may generate sufficient free polymerases or terminal proteins to give rise to IFN-resistant cells. Clinically, this may be one of the mechanisms by which patients develop resistance to IFN therapy during chronic viral infection. Considered together, our results are of clinical importance in the treatment of viral hepatitis and liver cancer. Another important observation in our study is the synergy between IFN-α and sodium butyrate in the induction of p21 WAF-1 expression. This protein was originally identified as a CDK2-interactive protein by using the yeast two-hybrid technique and was found to be a CDK inhibitor (Harper et al, 1993) . Subsequently, accumulating data suggested that p21 WAF-1 is a critical mediator of p53-mediated G1 phase arrest (El-Deiry et al, 1993 , 1994 . Many human cancer cells (including hepatoma cells) harbour mutant p53 proteins, these cells do not arrest in the G1 phase and do not accumulate p21 WAF-1 after DNA-damaging agent treatment, thus resulting in de-regulated cell growth control. It has been demonstrated that p21 WAF-1 expression can be induced via p53-independent pathways and enforced expression of this protein in cancer cells harbouring mutant p53 proteins may induce G1 phase arrest and inhibit tumour growth (Xiong et al, 1993; Harper et al, 1995) . Recent study showed that IFNs might trigger expression of p21 WAF-1 via STAT1 sites (Chin et al, 1996) . Thus, sodium butyrate may act via up-regulation of STAT1 expression to enhance IFN-α-induced p21 WAF-1 expression in PLC/PRF/5 cells. However, it is also possible that sodium butyrate may act via Sp1 sites independently to activate p21 WAF-1 expression as reported recently (Nakano et al, 1997) . Study of the collaboration between different consensus sites in p21 WAF-1 promoter will be helpful for the understanding of regulation of p21 WAF-1 expression in cells receiving different stimuli or insults. Induction of a DNA ladder pattern of DNA fragmentation by sodium butyrate/IFN-α combination in PLC/PRF/5 cells. Cells were cultured in sodium butyrate (1 mM) or IFN-α or a combination of these two drugs for 3 days. Cells were collected in a lysis buffer and genomic DNA was extracted. DNA samples were subjected to agarose gel electrophoresis, stained with ethidium bromide and visualized under UV light 
